Gastroenteropancreatic Neuroendocrine Tumor Clinical Trials

8 recruiting

Gastroenteropancreatic Neuroendocrine Tumor Trials at a Glance

12 actively recruiting trials for gastroenteropancreatic neuroendocrine tumor are listed on ClinicalTrialsFinder across 6 cities in 13 countries. The largest study group is Phase 3 with 4 trials, with the heaviest enrollment activity in Clichy, Detroit, and Beijing. Lead sponsors running gastroenteropancreatic neuroendocrine tumor studies include Jiangsu HengRui Medicine Co., Ltd., Hospices Civils de Lyon, and CSPC ZhongQi Pharmaceutical Technology Co., Ltd..

Browse gastroenteropancreatic neuroendocrine tumor trials by phase

Treatments under study

About Gastroenteropancreatic Neuroendocrine Tumor Clinical Trials

Looking for clinical trials for Gastroenteropancreatic Neuroendocrine Tumor? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Gastroenteropancreatic Neuroendocrine Tumor trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Gastroenteropancreatic Neuroendocrine Tumor clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting
Phase 3

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

Somatostatin Receptor Positive (SSTR+)Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Novartis Pharmaceuticals240 enrolled65 locationsNCT06784752
Recruiting
Phase 1Phase 2

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors

ParagangliomaPheochromocytomaMeningioma+4 more
Perspective Therapeutics300 enrolled19 locationsNCT05636618
Recruiting
Phase 2Phase 3

Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors

Gastroenteropancreatic Neuroendocrine Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.298 enrolled1 locationNCT07165886
Recruiting
Phase 3

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Advanced Gastroenteropancreatic Neuroendocrine Tumor
Jiangsu HengRui Medicine Co., Ltd.220 enrolled1 locationNCT05884255
Recruiting

Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors

Neuroendocrine TumorsGastroenteropancreatic Neuroendocrine Tumor
Methodist Health System50 enrolled2 locationsNCT04090034
Recruiting

Nutritional Status Assessment in Adult Patients Followed for Gastroenteropancreatic Neuroendocrine Tumors at Strasbourg University Hospital

Gastroenteropancreatic Neuroendocrine Tumor
University Hospital, Strasbourg, France100 enrolled1 locationNCT07302100
Recruiting
Phase 2

IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers

Peritoneal MesotheliomaAnaplastic Thyroid CarcinomasCarcinoid Tumor+3 more
Hospices Civils de Lyon154 enrolled15 locationsNCT06790706
Recruiting
Not Applicable

Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort

RadiotherapyGastroenteropancreatic Neuroendocrine Tumor
Assistance Publique - Hôpitaux de Paris80 enrolled5 locationsNCT06256705
Recruiting
Phase 1

Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery

Gastroenteropancreatic Neuroendocrine Tumor
Stanford University10 enrolled1 locationNCT04609592
Recruiting
Phase 3

Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors

Advanced Gastroenteropancreatic Neuroendocrine Tumor
Jiangsu HengRui Medicine Co., Ltd.66 enrolled1 locationNCT06091748
Recruiting
Phase 4

Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients

Gastroenteropancreatic Neuroendocrine Tumor
University Hospital, Antwerp270 enrolled19 locationsNCT05701241
Recruiting

68Ga-DOTATOC PET for the Evaluation of Gastroenteropancreatic Neuroendocrine Tumours

Gastroenteropancreatic Neuroendocrine Tumor
IRCCS San Raffaele300 enrolled1 locationNCT06155318